1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD) is a neurodegenerative disorder and the most common cause of dementia ([@bb0125]; [@bb0175]). The disease presumably starts with the aggregation of amyloid beta, after which it can take up to 15 years for the dementia syndrome to manifest ([@bb0010]; [@bb0095]). Because amyloid becomes abnormal very early in the disease when cognition is still normal, it is difficult to estimate when the disease has started and where individuals are in their disease trajectory. As such, when modeling disease progression solely based on time from first assessment, individuals\' positions in their disease trajectory are not taken into account. Models that account for disease severity might more accurately estimate disease specific outcome measures within individuals, such as grey matter (GM) atrophy rates.

GM atrophy is thought of as a close biological substrate of decline in cognitive functioning ([@bb0070]; [@bb0195]). Still, most studies model changes in GM atrophy and cognitive decline separately, and not within individuals. Although changes over time in both variables are correlated with each other ([@bb0080]; [@bb0140]; [@bb0190]), these associations do not account for inter-individual differences in disease severity. Modeling change in both GM atrophy and cognition *within* individuals, [@bb0075] used Mini-Mental State Examination (MMSE) at baseline as a proxy of disease severity to align individuals according to their initial disease stage and investigated the associations of rates of hippocampal volume and annualized cognitive decline in the MMSE. Results were in line with previous findings of increasing hippocampal atrophy with advancing disease stages, supporting tests of cognitive performance as a continuous approximation for disease severity. Other brain areas in addition to the hippocampus are, however, likely related to disease progression ([@bb0155]; [@bb0210]; [@bb0220]). Another complicating factor is that GM volume declines with age ([@bb0005]; [@bb0045]; [@bb0055]; [@bb0115]). It remains unclear, however, whether atrophy in more widespread cortical areas is related to decline in MMSE within individuals, and to which extent such associations are specific for AD and influenced by effects of time and/or aging.

In this study we therefore analyzed longitudinal changes in GM volumes using MMSE as an anchor point for individual disease severity and investigated how these associations differed from those using follow-up time or age in individuals with abnormal amyloid across the clinical spectrum. We further studied whether such associations were specific for distinct anatomical regions and for amyloid pathology.

2. Material and methods {#s0010}
=======================

2.1. Participants {#s0015}
-----------------

Data used in the preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu>). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer\'s disease (AD). ADNI was approved by the institutional review board of all participating institutions and written informed consent was obtained from all participants at each site.

Details of clinical diagnoses have been previously described elsewhere ([@bb0170]; for a general procedures manual see <https://adni.loni.usc.edu/wp-content/uploads/2010/09/ADNI_GeneralProceduresManual.pdf>). Briefly, classification into the clinical stages, cognitively normal (CN), and MCI was based on screening with the CDR, MMSE and delayed recall on Logical Memory II subscale of the Wechsler Memory Scale-Revised (adjusted for education). Additionally, MCI and dementia participants had to have a memory complaint. Dementia patients had to have a clinical diagnosis of probable AD according to the NINCDS-ADRDA criteria ([@bb0145]).

We selected participants across the different clinical stages of the AD continuum (preclinical AD, prodromal AD, AD dementia) from ADNI-1/GO/-2 with abnormal amyloid biomarkers at baseline (PiB, AV45-PET or amyloid β 1--42 CSF) and ≥0.9 years of repeated MRI available. A total of 523 patients met inclusion criteria and had MRI scans of sufficient quality available.

We used repeated MMSE as a measure for general cognitive functioning to align individuals according to their disease severity. Over a median follow-up time of 2 years (interquartile range (IQR): 1.6--4), a total of 2281 MMSE assessments were available with a median number of neuropsychological follow-up of 4 (IQR: 3--5).

Additionally, we repeated analyses in a sample of individuals that fulfilled the same inclusion criteria but with normal amyloid markers at baseline (*n* = 387). For these individuals, a total of 1710 MMSE assessments were available (median (IQR) follow-up time: 2.6 (2--4); median (IQR) number of assessments: 4 (3.8--5)).

2.2. Image acquisition and pre-processing {#s0020}
-----------------------------------------

Image acquisition details and initial preprocessing are described elsewhere (<http://adni.loni.usc.edu/methods/mri-analysis/;>[@bb0065]). All 3D T1-weighted structural scans available for the selected participants were downloaded from the ADNI LONI Image & Data Archive (IDA) \[date of last access: 29.03.2017\]. Scans that were preprocessed with gradwarping, B1 correction and/or N3 scaling were downloaded for the present analyses. If available and of sufficient quality, we chose the original sequence over the repeated scan acquisition and the scans with the most preprocessing steps for each acquisition date. In total, 2590 scans met inclusion criteria (*n* = 1988 scans for individuals with normal baseline amyloid). Within individuals, scans were included when they had the same field strength. First, all images were reoriented with FSL (v5.0.6). Next, a subject-specific median template image from all follow-up scans was created with Freesurfer (v5.3.0) to reduce bias in longitudinal registration ([@bb0180]). Further preprocessing was performed in SPM12. For each subject, scans were co-registered to the subject-specific median template image, and then segmented into GM, white matter and cerebrospinal fluid with the Markov Random Fields (MRF) parameter set to 2 and default settings for all other parameters. Next, the automated anatomical labeling atlas (AAL; [@bb0205]) was warped from standard space to subject space using the subject specific inversed normalization parameters. For each of the 90 cortical and subcortical AAL areas we calculated regional GM volumes. Total intracranial volume (TIV) was computed as the sum of GM, white matter and cerebrospinal fluid volumes in cm^3^. All GM segmentations and subject-specific atlases were visually inspected for quality.

2.3. PET/CSF analysis {#s0025}
---------------------

Participants were classified as having normal or abnormal amyloid based on amyloid PET results (for processing details see <http://adni.loni.usc.edu/methods/pet-analysis/;>[@bb0085]; [@bb0090]), and when PET was unavailable, on CSF amyloid β 1--42 results ([@bb0185]). The threshold for abnormal amyloid was for PiB SUVRs \>1.5 (available for *n* = 5, 0.6%), for AV45 SUVR \>1.1 (available for *n* = 631, 69%) (both SUVR calculated in reference to the cerebellum; [@bb0085]; [@bb0090]) and for CSF amyloid β 1--42 levels \<192 pg/ml (available for *n* = 850, 94%) ([@bb0185]).

2.4. Statistical analyses {#s0030}
-------------------------

Comparisons of baseline characteristics between baseline clinical stages (preclinical AD, prodromal AD, AD dementia) were performed with one-way ANOVA, Kruskal tests or chi-squared tests when appropriate. If significant differences were found, we performed post-hoc comparisons with Tukey\'s tests or Dunn\'s tests with *p* values adjusted for multiple comparisons with the Hochberg procedure.

We tested three models taking time, age or MMSE as predictor for change in GM volume (outcome) with linear mixed effects using the R package 'lme4' ([@bb0015]) (see also [Fig. 1](#f0005){ref-type="fig"}): Model 1 included time as the predictor and subject-specific random intercepts and random slopes for time:$$\ \mathit{GM}\ \mathit{volume} = \beta_{\mathit{Intercept}} + \beta_{\mathit{Time}}\mathit{Time} + \beta_{C1}C_{1} + \beta_{C2}C_{2} + \beta_{C3}C_{3} + \beta_{C4}C_{4} + \beta_{C5}C_{5} + \left( {1 + \mathit{Time}} \middle| \mathit{Subject} \right)$$Fig. 1Hypothesized difference between taking time, age versus MMSE as a measure for disease progression. For the time model, we included follow-up time (in years) as the predictor, a random intercept for subjects and subject-specific random slopes for follow-up time. For the age model, we included age as the predictor, a random intercept for subjects and subject-specific random slopes for age. For the MMSE model, we included MMSE as a predictor, a random intercept for subjects and subject-specific random slopes for MMSE. We additionally included an interaction effect with baseline clinical stage (i.e., CN, MCI, dementia) to estimate cross-sectional and longitudinal differences between the different clinical stages. Models were corrected for age at baseline (time and MMSE model), sex, education and field strength.Fig. 1

Model 2 included age (longitudinal, i.e., baseline age + follow-up time in years) as the predictor and subject-specific random intercepts and random slopes for age:$$\ \mathit{GM}\ \mathit{volume} = \beta_{\mathit{Intercept}} + \beta_{\mathit{Age}}\mathit{Age} + \beta_{C2}C_{2} + \beta_{C3}C_{3} + \beta_{C4}C_{4} + \beta_{C5}C_{5} + \left( {1 + \mathit{Age}} \middle| \mathit{Subject} \right)$$

Model 3 included MMSE as the predictor and subject-specific random intercepts and random slopes for MMSE:$$\ \mathit{GM}\ \mathit{volume} = \beta_{\mathit{Intercept}} + \beta_{\mathit{MMSE}}\mathit{MMSE} + \beta_{C1}C_{1} + \beta_{C2}C_{2} + \beta_{C3}C_{3} + \beta_{C4}C_{4} + \beta_{C5}C_{5} + \left( {1 + \mathit{MMSE}} \middle| \mathit{Subject} \right)$$

Analyses were adjusted for the potential influence of age at baseline *C*~*1*~ (model 1 and model 3), gender *C*~*2*~, education *C*~*3*~, field strength *C*~*4*~ and baseline total intracranial volume *C*~*5*~. Because it is conceivable that baseline clinical stage (i.e., CN, MCI, AD dementia) may influence the results and in order to assess potential non-linear effects for MMSE, we repeated the models with an additional interaction term for time × diagnosis, age × diagnosis and MMSE × diagnosis, respectively. We only considered paired MRI and MMSE data for these analyses (*n* = 2281 observations for individuals with abnormal amyloid, *n* = 1710 observations for individuals with normal amyloid). For all models we used an unstructured covariance matrix. Clinical stage differences in estimated marginal means and trends are reported with the emmeans package ([@bb0120]). Raw scores of MMSE and GM volumes were used to aid interpretation. Models were repeated for all 90 AAL regions. In order to standardize effects across the different regions, local volumes were normalized to the mean values of cognitively normal individuals with normal amyloid at baseline. Type III analysis of variance with Satterthwaite\'s method were used to estimate main effects. For each model, local analyses were corrected for multiple testing with the false discovery rate (FDR) procedure ([@bb0020]). To investigate whether longitudinal changes in MMSE or grey matter volumes were different depending on amyloid abnormality we refit all models for the total sample including baseline amyloid status as a main term and interaction effect with the respective predictor. Analyses were then repeated for individuals with normal amyloid markers to investigate whether observed effects were specific for the presence of amyloid pathology. We also investigated whether differences in field strength impacted our results and repeated all main models stratified by field strength. Finally, we performed model fit comparisons for non-nested linear mixed models based on differences in AIC and the likelihood ratio test ([@bb0215]) with the package 'nonnest2'. R^2^ for fixed and random effects were estimated with the 'MuMIn' package ([@bb0100]; [@bb0160]). Statistical analyses were performed in R (version 3.4.4, 2018-03-15) and Surf Ice (version 2017-08-08) was used to visualize regional results.

3. Results {#s0035}
==========

3.1. Sample description {#s0040}
-----------------------

In total 523 individuals with abnormal amyloid were included: 100 preclinical AD participants, 288 individuals with prodromal AD and 135 patients with AD-type dementia ([Table 1](#t0005){ref-type="table"}). Participants were on average 74 ± 7 years old and 48% were female.Table 1Demographic and clinical characteristics of the included sample.Table 1Total group (*n* = 523)Preclinical AD (*n* = 100, 19%)Prodromal AD (*n* = 288, 55%)AD dementia (*n* = 135, 26%)Pairwise comparisonsFemale253 (48%)64 (64%)124 (43%)65 (48%)CN \> MCI; CN \> ADAge, years73.83 (6.84)75.44 (5.57)73.19 (6.91)73.99 (7.37)CN \> MCIEducation, years16 (14--18)16 (14--18)16 (14--18)16 (13--18)n.s.Progression to MCI19 (4%)19 (19%)n.a.n.a.n.a.Progression to dementia154 (29%)7 (7%)147 (51%)n.a.n.a.APOE4 allele (0/≥1)177 (34%)/346 (66%)53 (53%)/47 (47%)96 (33%)/192 (67%)28 (21%)/107 (79%)CN \< MCI; CN \< AD; MCI \< AD [c](#tf0015){ref-type="table-fn"}AV45 PET SUVR [a](#tf0005){ref-type="table-fn"}1.39 (0.17)1.34 (0.18)1.38 (0.16)1.45 (0.16)CN \< AD; MCI \< ADAbnormal AV45 PET \>1.11 SUVR [a](#tf0005){ref-type="table-fn"}333 (100%)70 (100%)189 (100%)74 (100%)n.a.CSF Aβ1--42, pg/ml [b](#tf0010){ref-type="table-fn"}139.78 (28.66)153.33 (35.36)139.95 (27.17)129.34 (21.28)CN \> MCI; CN \> AD; MCI \> ADAbnormal Aβ1--42 \< 192 pg/ml [b](#tf0010){ref-type="table-fn"}469 (95%)81 (87%)263 (96%)125 (100%)CN \< MCI; CN \< AD; MCI \< ADCSF total tau, pg/ml [b](#tf0010){ref-type="table-fn"}110.17 (55.31)77.71 (36.49)110.47 (52.7)133.65 (60.54)CN \< MCI; CN \< AD; MCI \< ADAbnormal total tau \>93 pg/ml [b](#tf0010){ref-type="table-fn"}273 (55%)27 (29%)153 (56%)93 (74%)CN \< MCI; CN \< AD; MCI \< ADFollow up time, years (ADNI)2 (1.6--4)2.1 (2--4)3 (2--4)1.5 (1--2)CN \> AD; MCI \> ADNumber of assessments (MRI and MMSE)4 (3--5)4 (3--5)5 (4--5.8)3 (3--4)CN \< MCI; CN \> AD; MCI \> ADField strength (3 T)1509 (65%)260 (61%)819 (59%)256 (55%)n.s.Total intracranial volume, cm^3^1451.67 (148.18)1435.76 (140.14)1463.19 (145.29)1438.89 (158.68)n.s.Grey matter volume, cm^3^582.91 (73.39)597.74 (66.4)593.53 (71.32)549.24 (72.67)CN \> AD; MCI \> ADHippocampal volume, cm^3^7.53 (1.42)8.36 (0.96)7.71 (1.3)6.54 (1.42)CN \> MCI; CN \> AD; MCI \> AD[^2][^3][^4][^5]

At baseline, AD-type dementia patients performed worst on the MMSE and had the lowest GM and hippocampal volumes, followed by prodromal AD and then preclinical AD ([Table 2](#t0010){ref-type="table"}). At a regional level, AD dementia patients had the lowest volumes in the medial temporal lobes, followed by prodromal AD and then preclinical AD participants (see Inline Supplementary Fig. 1a).Table 2Cross-sectional and longitudinal estimates for MMSE, grey matter and hippocampal volumes over follow-up time.Table 2Longitudinal estimatesCross-sectional estimatesCross-sectional differencesLongitudinal estimatesLongitudinal differencesTotal groupPreclinical ADProdromal ADAD dementiaPreclinical AD - Prodromal ADProdromal AD - AD dementiaPreclinical ADProdromal ADAD dementiaPreclinical AD - Prodromal ADProdromal AD - AD dementiaMMSE−1.29 ± 0.08[⁎⁎⁎](#tf0030){ref-type="table-fn"}28.75 ± 0.3[⁎⁎⁎](#tf0030){ref-type="table-fn"}25.92 ± 0.18[⁎⁎⁎](#tf0030){ref-type="table-fn"}20.19 ± 0.27[⁎⁎⁎](#tf0030){ref-type="table-fn"}−2.82[⁎⁎⁎](#tf0030){ref-type="table-fn"}−5.74[⁎⁎⁎](#tf0030){ref-type="table-fn"}−0.27 ± 0.16−1.08 ± 0.1[⁎⁎⁎](#tf0030){ref-type="table-fn"}−2.38 ± 0.18[⁎⁎⁎](#tf0030){ref-type="table-fn"}−0.8[⁎⁎⁎](#tf0030){ref-type="table-fn"}−1.3[⁎⁎⁎](#tf0030){ref-type="table-fn"}\[−16.17\]\[95.09\]\[146.55\]\[73.78\]\[−1.71\]\[−11.33\]\[−13.46\]Grey matter volume in cm^3^−12.23 ± 0.47[⁎⁎⁎](#tf0030){ref-type="table-fn"}596.63 ± 5.43[⁎⁎⁎](#tf0030){ref-type="table-fn"}570.16 ± 3.21[⁎⁎⁎](#tf0030){ref-type="table-fn"}530.72 ± 4.6[⁎⁎⁎](#tf0030){ref-type="table-fn"}−26.47[⁎⁎⁎](#tf0030){ref-type="table-fn"}−39.44[⁎⁎⁎](#tf0030){ref-type="table-fn"}−6.99 ± 0.95[⁎⁎⁎](#tf0030){ref-type="table-fn"}−12.52 ± 0.57[⁎⁎⁎](#tf0030){ref-type="table-fn"}−16.53 ± 1.15[⁎⁎⁎](#tf0030){ref-type="table-fn"}−5.53[⁎⁎⁎](#tf0030){ref-type="table-fn"}−4.01[⁎⁎](#tf0025){ref-type="table-fn"}\[−26.18\]\[109.85\]\[177.64\]\[115.4\]\[−7.33\]\[−22.07\]\[−14.37\]Atrophy rate (GM)−2.1% (−2.26%, −1.94%)−1.17% (−1.48%, −0.86%)−2.11% (−2.3%, −1.92%)−3.01% (−3.42%, −2.6%)Hippocampal volume in cm^3^−0.32 ± 0.01[⁎⁎⁎](#tf0030){ref-type="table-fn"}8.26 ± 0.12[⁎⁎⁎](#tf0030){ref-type="table-fn"}7.15 ± 0.07[⁎⁎⁎](#tf0030){ref-type="table-fn"}5.98 ± 0.1[⁎⁎⁎](#tf0030){ref-type="table-fn"}−1.11[⁎⁎⁎](#tf0030){ref-type="table-fn"}−1.18[⁎⁎⁎](#tf0030){ref-type="table-fn"}−0.17 ± 0.02[⁎⁎⁎](#tf0030){ref-type="table-fn"}−0.32 ± 0.01[⁎⁎⁎](#tf0030){ref-type="table-fn"}−0.45 ± 0.02[⁎⁎⁎](#tf0030){ref-type="table-fn"}−0.15[⁎⁎⁎](#tf0030){ref-type="table-fn"}−0.12[⁎⁎⁎](#tf0030){ref-type="table-fn"}\[−34.06\]\[69.25\]\[101.46\]\[59.22\]\[−9\]\[−28.71\]\[−22.56\]Atrophy rate (Hippocampus)−4.28% (−4.53%, −4.04%)−2.03% (−2.47%, −1.59%)−4.18% (−4.46%, −3.89%)−6.81% (−7.41%, −6.22%)[^6][^7][^8]

3.2. Model 1 results: changes in grey matter volumes and MMSE as a function of time {#s0045}
-----------------------------------------------------------------------------------

We first modeled changes in GM volumes and MMSE separately over time. [Fig. 2](#f0010){ref-type="fig"}a shows the change over time in MMSE and GM volume according to baseline clinical stage. Over time, the total sample showed declines of −1.29 ± 0.08 points per year on the MMSE and −12.23 ± 0.47 cm^3^ or −2.1% (95%CI; −2.26%, −1.94%) per year in GM volume (all *p* \< .001; [Table 2](#t0010){ref-type="table"}). Patients with AD-type dementia showed the fastest decline in the MMSE and GM volume (β ± SE; −2.38 ± 0.18 points per year and −16.53 ± 1.15 cm^3^ or −3.01% (95%CI; −3.42%, −2.6%) per year; all *p* \< .001), followed by prodromal AD (β ± SE; −1.08 ± 0.1 points per year and −12.52 ± 0.57 cm^3^ or −2.11% (95%CI; −2.3%, −1.92%) per year; all *p* \< .001) and then preclinical AD (β ± SE, −0.27 ± 0.16 points per year; *p* \> .05; −6.99 ± 0.95 cm^3^ or −1.17% (95%CI; −1.48%, −0.86%) per year; *p* \< .001). For annual atrophy rates at a regional level, we found a widespread atrophy pattern with the strongest associations for decline over time for the bilateral hippocampi, insulae and Rolandic opercula (all p~FDR~ \< 0.001; [Fig. 3](#f0015){ref-type="fig"}a). AD dementia participants showed faster atrophy over time mostly in temporal regions as compared to prodromal AD participants, while the atrophy pattern was similar between prodromal and preclinical AD individuals with faster atrophy for prodromal AD (all p~FDR~ \< 0.05).Fig. 2Predicted changes in grey matter volumes and cognitive functioning (a) as a function of follow-up time, (b) as a function of aging and (c) as a function of MMSE for the baseline clinical stages in individuals with abnormal amyloid markers. Predicted values are based on raw values and were estimated with linear mixed models. The models included the terms age (for the time and MMSE models), sex, education, field strength and total intracranial volume (for grey matter volumes), and time, age or MMSE as predictor, and the interaction term predictor × diagnosis. Regression lines are based on cross-sectional (intercepts) and longitudinal (slopes) estimates of the respective model and are based on estimated marginal means for the clinical stages. Vertical line in (b) indicates mean age at baseline for the total sample.GM, grey matter.Fig. 2Fig. 3Surface plots of longitudinal associations of local grey matter volumes with (a) follow-up time, (b) aging and (c) decline in MMSE over time for the total groups and per baseline clinical stage. The color bar indicates the effect sizes as t ratios based on local GM volumes standardized to the mean values of cognitively normal individuals with normal amyloid at baseline (for descriptive data see Inline Supplementary Table 7) and were obtained with linear mixed models. Analyses were adjusted for age (for time and MMSE models), sex, education, field strength and total intracranial volume. Note that t ratios indicate the strength of the effect and do not correspond to betas. For associations in the total group and baseline clinical stages, negative values indicate steeper grey matter atrophy with increasing time or age and positive values indicate steeper grey matter atrophy with worsening MMSE. For comparison of clinical stages, negative values indicate steeper atrophy rates for e.g. prodromal AD as compared to preclinical AD and positive values indicate less steep atrophy rates for e.g. prodromal AD as compared to preclinical AD. Subcortical structures are plotted in ventricular areas as approximation. The model for the association with MMSE for the total group did not converge for the left supramarginal gyrus.L, left hemisphere; R, right hemisphere; ^⁎^p~uncorrected~ \< 0.05.Fig. 3

3.3. Model 2 results: changes in grey matter volumes and MMSE as a function of aging {#s0050}
------------------------------------------------------------------------------------

When aligning individuals according to their age, we observed smaller estimates as compared to modeling change as a function of time, with −0.28 ± 0.03 points per year of age on the MMSE and −8.87 ± 0.34 cm^3^ or 1.52% (95%CI; −1.65%, −1.4%) per year of age in GM volume (all *p* \< .001: [Table 3](#t0015){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}b). Across clinical stages, individuals with prodromal AD showed the fastest decline over aging for MMSE (β ± SE; −0.22 ± 0.03 points per year of age) and GM volume (−9.6 ± 0.42 cm^3^ or −1.62% (95%CI; −1.76%, −1.48%) per year of age) compared to AD-type dementia (MMSE: −0.09 ± 0.04 per year of age, *p* \> .05; GM: -7.94 ± 0.77 cm^3^ or −1.45% (95%CI; −1.72%, −1.17%) per year of age, *p* \< .001) and preclinical AD participants (MMSE: −0.14 ± 0.05 per year of age, *p* \< .05; GM: -6.3 ± 0.74 cm^3^ or −1.05% (95%CI; −1.3%, −0.81%) per year of age; *p* \< .001). Similar to the time model, we found widespread regional effects for decline in GM volumes with age, with the strongest effects found for the bilateral hippocampi, insulae and Rolandic opercula (all p~FDR~ \< 0.001; [Fig. 3](#f0015){ref-type="fig"}b). Compared to AD dementia, prodromal AD participants showed faster atrophy in mostly frontoparietal areas, while preclinical and prodromal AD showed a largely similar atrophy pattern albeit with faster rates for prodromal AD (all p~FDR~ \< 0.05).Table 3Cross-sectional and longitudinal estimates for MMSE, grey matter and hippocampal volumes over aging.Table 3Longitudinal estimatesCross-sectional estimatesCross-sectional differencesLongitudinal estimatesLongitudinal differencesTotal groupPreclinical ADProdromal ADAD dementiaPreclinical AD - Prodromal ADProdromal AD - AD dementiaPreclinical ADProdromal ADAD dementiaPreclinical AD - Prodromal ADProdromal AD - AD dementiaMMSE−0.28 ± 0.03[⁎⁎⁎](#tf0045){ref-type="table-fn"}29.03 ± 0.31[⁎⁎⁎](#tf0045){ref-type="table-fn"}25.75 ± 0.18[⁎⁎⁎](#tf0045){ref-type="table-fn"}21.62 ± 0.27[⁎⁎⁎](#tf0045){ref-type="table-fn"}−3.28[⁎⁎⁎](#tf0045){ref-type="table-fn"}−4.13[⁎⁎⁎](#tf0045){ref-type="table-fn"}−0.14 ± 0.05[⁎](#tf0035){ref-type="table-fn"}−0.22 ± 0.03[⁎⁎⁎](#tf0045){ref-type="table-fn"}−0.09 ± 0.04−0.080.13[⁎](#tf0035){ref-type="table-fn"}\[−9.41\]\[95.08\]\[141.56\]\[79.02\]\[−2.69\]\[−8.29\]\[−2.23\]Grey matter volume in cm^3^−8.87 ± 0.34[⁎⁎⁎](#tf0045){ref-type="table-fn"}600.75 ± 6.78[⁎⁎⁎](#tf0045){ref-type="table-fn"}563.06 ± 4.1[⁎⁎⁎](#tf0045){ref-type="table-fn"}532.19 ± 6[⁎⁎⁎](#tf0045){ref-type="table-fn"}−37.7[⁎⁎⁎](#tf0045){ref-type="table-fn"}−30.87[⁎⁎⁎](#tf0045){ref-type="table-fn"}−6.3 ± 0.74[⁎⁎⁎](#tf0045){ref-type="table-fn"}−9.6 ± 0.42[⁎⁎⁎](#tf0045){ref-type="table-fn"}−7.94 ± 0.77[⁎⁎⁎](#tf0045){ref-type="table-fn"}−3.3[⁎⁎⁎](#tf0045){ref-type="table-fn"}1.66\[−25.78\]\[88.55\]\[137.37\]\[88.68\]\[−8.56\]\[−22.71\]\[−10.32\]Atrophy rate (GM)−1.52% (−1.65%, −1.4%)−1.05% (−1.3%, −0.81%)−1.62% (−1.76%, −1.48%)−1.45% (−1.72%, −1.17%)Hippocampal volume in cm^3^−0.28 ± 0.01[⁎⁎⁎](#tf0045){ref-type="table-fn"}8.53 ± 0.2[⁎⁎⁎](#tf0045){ref-type="table-fn"}6.96 ± 0.12[⁎⁎⁎](#tf0045){ref-type="table-fn"}5.96 ± 0.18[⁎⁎⁎](#tf0045){ref-type="table-fn"}−1.56[⁎⁎⁎](#tf0045){ref-type="table-fn"}−1[⁎⁎⁎](#tf0045){ref-type="table-fn"}−0.16 ± 0.02[⁎⁎⁎](#tf0045){ref-type="table-fn"}−0.29 ± 0.01[⁎⁎⁎](#tf0045){ref-type="table-fn"}−0.35 ± 0.02[⁎⁎⁎](#tf0045){ref-type="table-fn"}−0.13[⁎⁎⁎](#tf0045){ref-type="table-fn"}−0.06[⁎⁎](#tf0040){ref-type="table-fn"}\[−33.58\]\[42.95\]\[58.37\]\[34.04\]\[−9.38\]\[−28.42\]\[−20.16\]Atrophy rate (Hippocampus)−3.73% (−3.96%, −3.51%)−1.95% (−2.36%, −1.54%)−3.79% (−4.05%, −3.52%)−5.43% (−5.95%, −4.9%)[^9][^10][^11][^12]

3.4. Model 3 results: changes in grey matter volumes as a function of MMSE {#s0055}
--------------------------------------------------------------------------

When modeling disease progression as a function of MMSE, we observed that steeper decline on the MMSE was correlated with steeper GM volume loss (β ± SE = 4.1 ± 0.25 cm^3^ or 0.7% (95%CI; 0.62%, 0.79%) per MMSE point, *p* \< .001; [Table 4](#t0020){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}c). Compared to modeling atrophy as a function of time, where individuals showed an atrophy rate of 2.1% and a 1.29 point reduction on MMSE per year (i.e., atrophy rate of 1.63% with 1 point decline on MMSE), when change in both variables was modeled *within* individuals, atrophy decreased much less with 0.71% decrease in GM volume per 1 point decline in MMSE score. When using age as a proxy for disease progression we, similarly to the model based on time, found steeper slopes for atrophy of 1.54% and a 0.27 point decline on MMSE per year (i.e., atrophy rate of 5.7% with 1 point decline on MMSE). This suggests that using time or age as a proxy for disease progression may result in overestimation of disease-related atrophy, which may not reflect individual decline on MMSE, as a proxy for disease progression. Across clinical stages, prodromal AD participants showed the strongest associations of MMSE and GM volume (β ± SE = 4.46 ± 0.33 cm^3^ per MMSE point, *p* \< .001) followed by AD dementia patients (β ± SE = 3.04 ± 0.48 cm^3^ per MMSE point, *p* \< .001) and preclinical AD (β ± SE = 2.64 ± 0.84 cm^3^ per MMSE point, *p* \< .01). Associations of GM volumes with MMSE did not depend on educational level (see Inline Supplementary Table 1).Table 4Cross-sectional and longitudinal estimates for grey matter and hippocampal volumes over MMSE.Table 4Longitudinal estimatesCross-sectional estimatesCross-sectional differencesLongitudinal estimatesLongitudinal differencesTotal groupPreclinical ADProdromal ADAD dementiaPreclinical AD - Prodromal ADProdromal AD - AD dementiaPreclinical ADProdromal ADAD dementiaPreclinical AD - Prodromal ADProdromal AD - AD dementiaGrey matter volume in cm^3^4.1 ± 0.25[⁎⁎⁎](#tf0060){ref-type="table-fn"}588.05 ± 5.53[⁎⁎⁎](#tf0060){ref-type="table-fn"}570.02 ± 2.94[⁎⁎⁎](#tf0060){ref-type="table-fn"}553.56 ± 4.34[⁎⁎⁎](#tf0060){ref-type="table-fn"}−18.03[⁎](#tf0050){ref-type="table-fn"}−16.46[⁎⁎](#tf0055){ref-type="table-fn"}2.64 ± 0.84[⁎⁎](#tf0055){ref-type="table-fn"}4.46 ± 0.33[⁎⁎⁎](#tf0060){ref-type="table-fn"}3.04 ± 0.48[⁎⁎⁎](#tf0060){ref-type="table-fn"}1.82−1.42[⁎](#tf0050){ref-type="table-fn"}\[16.23\]\[106.37\]\[194.14\]\[127.58\]\[3.16\]\[13.71\]\[6.34\]Atrophy rate (GM)0.7% (0.62%, 0.79%)0.44% (0.17%, 0.72%)0.75% (0.64%, 0.86%)0.55% (0.38%, 0.72%)Hippocampal volume in cm^3^0.11 ± 0.01[⁎⁎⁎](#tf0060){ref-type="table-fn"}7.94 ± 0.12[⁎⁎⁎](#tf0060){ref-type="table-fn"}7.12 ± 0.06[⁎⁎⁎](#tf0060){ref-type="table-fn"}6.56 ± 0.09[⁎⁎⁎](#tf0060){ref-type="table-fn"}−0.82[⁎⁎⁎](#tf0060){ref-type="table-fn"}−0.56[⁎⁎⁎](#tf0060){ref-type="table-fn"}0.09 ± 0.02[⁎⁎⁎](#tf0060){ref-type="table-fn"}0.12 ± 0.01[⁎⁎⁎](#tf0060){ref-type="table-fn"}0.08 ± 0.01[⁎⁎⁎](#tf0060){ref-type="table-fn"}0.03−0.04[⁎⁎](#tf0055){ref-type="table-fn"}\[21.37\]\[67.23\]\[112.68\]\[70.65\]\[5.16\]\[18.16\]\[8.05\]Atrophy rate (Hippocampus)1.49% (1.34%, 1.63%)1.06% (0.66%, 1.46%)1.55% (1.39%, 1.72%)1.19% (0.9%, 1.48%)[^13][^14][^15][^16]

At a regional level, when modeling atrophy as a function of decline in MMSE, the strongest associations were observed in the bilateral hippocampi, superior and middle temporal poles and insulae (all p~FDR~ \< 0.001; [Fig. 3](#f0015){ref-type="fig"}c). The anatomical pattern of associations between decline in MMSE and atrophy was similar for AD dementia and prodromal AD patients, albeit with stronger associations for prodromal AD compared to AD dementia patients especially in the left middle cingulate, Rolandic operculum, hippocampus and right inferior occipital gyrus (p~FDR~ \< 0.05). Compared to preclinical AD, prodromal AD patients showed stronger associations of decreasing MMSE and atrophy in the right inferior temporal gyrus (p~uncorrected~ = 0.04).

We further investigated whether the observed association with MMSE, as a proxy for disease severity, could be explained by the effect of follow-up time or aging. When we repeated the model additionally accounting for time or age, associations of MMSE with GM volumes remained significant for the total group and for individuals with prodromal AD and AD dementia specifically (see Inline Supplementary Tables 2 and 3), suggesting that modeling atrophy as a function of MMSE in more advanced disease stages can explain variance in atrophy in addition to time or aging. Similarly, refitting time and age models with longitudinal measures of MMSE resulted in similar effects as compared to the models that were not adjusted for within-individual cognitive decline (see Inline Supplementary Tables 4 and 5), suggesting that all measures can explain part of the variance in grey matter atrophy. Model fit for all refitted models was significantly improved by additionally adding time, age or MMSE, respectively.

3.5. Changes in grey matter volumes as a function of time, aging and MMSE in individuals with normal amyloid {#s0060}
------------------------------------------------------------------------------------------------------------

In order to investigate whether slopes in outcome measures differed for individuals with abnormal and normal amyloid, we included baseline amyloid abnormality as interaction effect with the respective predictor. In all models, longitudinal slopes for MMSE, grey matter atrophy rates were steeper for individuals with abnormal amyloid as compared to those with normal amyloid (see Inline Supplementary Table 6). We subsequently repeated analyses in a sample of 387 individuals with normal amyloid markers (190 CN, 180 MCI, 17 individuals with dementia; see Inline Supplementary Table 7 for demographic and clinical characteristics).

For these participants we found a slower decline in MMSE (β ± SE; −0.09 ± 0.03 points per year; *p* \< .01) and a slower decline in GM volume over time (β ± SE; −5.32 ± 0.33 cm^3^ or −0.86% (95%CI; −0.97%, −0.76%) per year; *p* \< .001) with 1.6 times weaker effect strength compared to individuals with abnormal amyloid markers (t ratio (abnormal amyloid): −26.18; t ratio (normal amyloid): −16.13; see Inline Supplementary Table 8 also for separate estimates for clinical stages). Using aging as a predictor we similarly found slower decline in MMSE (β ± SE; −0.04 ± 0.01 points per year; *p* \< .001) and GM volume (β ± SE; −4.85 ± 0.25 cm^3^ or −0.79% (95%CI; −0.87%, −0.71%) per year; *p* \< .001) with 1.3 times weaker effect strength for individuals with normal amyloid compared to those with abnormal amyloid (t ratio (abnormal amyloid): −25.78; t ratio (normal amyloid): −19.68; see Inline Supplementary Table 9). The anatomical pattern for regional volume loss over time or aging was similarly widespread compared to those observed for abnormal amyloid individuals, while we found reduced differences between the clinical stages ([Fig. 4](#f0020){ref-type="fig"}a--b; see Inline Supplementary Fig. 2 for cross-sectional associations). When modeling GM atrophy as a function of MMSE, we found that an atrophy rate of only 0.13% (95%CI; 0.01%, 0.25%) was directly related to decline on the MMSE (β ± SE; 0.83 ± 0.37 cm^3^ per MMSE point; *p* \< .05). Importantly, this association was of 7.2 times weaker effect strength compared to individuals with abnormal amyloid (t ratio (abnormal amyloid): 16.23; t ratio (normal amyloid): 2.24; [Table 5](#t0025){ref-type="table"}), indicating that associations with MMSE were more specific for amyloid pathology than associations with time or age. At a regional level, we only found few associations between decreasing MMSE and atrophy and mean effects were of 7 times weaker strength compared to the abnormal amyloid group ([Fig. 4](#f0020){ref-type="fig"}c). The difference in the anatomical patterns and weaker associations further suggest that observed associations between decline in GM volume and MMSE are specific for individuals with abnormal amyloid.Fig. 4Surface plots of longitudinal associations of local grey matter volumes with (a) follow-up time, (b) aging and (c) decline in MMSE over time for the total groups and per baseline clinical stage in individuals with normal amyloid. The color bar indicates the effect sizes as t ratios based on local GM volumes standardized to the mean values of cognitively normal individuals with normal amyloid at baseline (for descriptive data see Inline Supplementary Table 7) and were obtained with linear mixed models. Analyses were adjusted for age (for time and MMSE models), sex, education, field strength and total intracranial volume. Note that t ratios indicate the strength of the effect and do not correspond to betas. For associations in the total group and baseline clinical stages, negative values indicate steeper grey matter atrophy with increasing time or age and positive values indicate steeper grey matter atrophy with worsening MMSE. For comparison of clinical stages, negative values indicate steeper atrophy rates for e.g. prodromal AD as compared to preclinical AD and positive values indicate less steep atrophy rates for e.g. prodromal AD as compared to preclinical AD. Subcortical structures are plotted in ventricular areas as approximation.L, left hemisphere; R, right hemisphere; ^⁎^p~uncorrected~ \< 0.05.Fig. 4Table 5Cross-sectional and longitudinal estimates for grey matter and hippocampal volumes over MMSE in individuals with normal amyloid.Table 5Longitudinal estimatesCross-sectional estimatesCross-sectional differencesLongitudinal estimatesLongitudinal differencesTotal groupCNMCIDementiaCN-MCIMCI-DementiaCNMCIDementiaCN-MCIMCI-DementiaGrey matter volume in cm^3^0.83 ± 0.37[⁎](#tf0065){ref-type="table-fn"}609.72 ± 3.65[⁎⁎⁎](#tf0075){ref-type="table-fn"}597.59 ± 3.89[⁎⁎⁎](#tf0075){ref-type="table-fn"}597.6 ± 12.63[⁎⁎⁎](#tf0075){ref-type="table-fn"}−12.13[⁎](#tf0065){ref-type="table-fn"}0.010.99 ± 0.620.66 ± 0.50.8 ± 1.4−0.330.15\[2.24\]\[166.93\]\[153.64\]\[47.3\]\[1.6\]\[1.31\]\[0.58\]Atrophy rate (GM)0.13% (0.01%, 0.25%)0.16% (−0.04%, 0.36%)0.11% (−0.05%, 0.27%)0.14% (−0.34%, 0.62%)Hippocampal volume in cm^3^0.02 ± 0.01[⁎⁎](#tf0070){ref-type="table-fn"}8.6 ± 0.08[⁎⁎⁎](#tf0075){ref-type="table-fn"}7.95 ± 0.08[⁎⁎⁎](#tf0075){ref-type="table-fn"}7.1 ± 0.26[⁎⁎⁎](#tf0075){ref-type="table-fn"}−0.66[⁎⁎⁎](#tf0075){ref-type="table-fn"}−0.85[⁎⁎](#tf0070){ref-type="table-fn"}0.02 ± 0.010.01 ± 0.010.02 ± 0.03−0.010.01\[2.67\]\[109.26\]\[94.5\]\[27.1\]\[1.7\]\[1.41\]\[0.77\]Atrophy rate (Hippocampus)0.22% (0.05%, 0.38%)0.22% (−0.04%, 0.47%)0.16% (−0.06%, 0.38%)0.31% (−0.49%, 1.1%)[^17][^18][^19][^20]

For each model and both samples (i.e., amyloid abnormal and normal) we then compared model fit statistics as based on differences in AIC and likelihood ratio tests, calculated explained variance R^2^ and estimated variances in random effects. For both samples, best model, indicated by lowest AIC and/or highest log-likelihood, was observed for models based on time, followed by models based on aging and then MMSE (see Inline Supplementary Table 10). Aging models explained most variance in declining grey matter volume, as indicated by marginal R^2^, followed by time and then MMSE. Variance in subject slopes of decline on MMSE was greatest for time models as compared to aging models. Variance in random slope effects was lowest for MMSE models, followed by aging and then time models, suggesting that modeling grey matter atrophy as a function of cognitive decline leads to less inter-individual variance in atrophy slopes, which may reflect that individuals are better aligned according to their disease severity.

4. Discussion {#s0065}
=============

In this study, we compared three different approaches to investigate longitudinal changes in GM volume: by using follow-up time, aging or MMSE, as an anchor point to align individuals according to their disease severity. Compared to modeling atrophy as a function of time or aging we observed less steep slopes when modeling disease progression based on change in MMSE. Associations with time, aging and MMSE generally remained after additionally correcting for the other predictors, suggesting that all measures explain part of the variance in GM atrophy. For the MMSE, associations were specific for individuals with amyloid pathology, suggesting that modeling longitudinal GM atrophy with MMSE as a proxy for disease progression might be specific for cognitive decline in individuals with evidence of AD pathology.

Previous studies taking time between first visit and follow-up to model disease progression found whole-brain atrophy rates of 0.4--0.7% for cognitively normal older individuals and of 0.6--2.2% for AD patients (see [@bb0050] for review), which are similar to our estimates of annual atrophy rates. Faster decline in annualized whole-brain atrophy rates were furthermore found to correlate with faster annualized change on the MMSE across individuals ([@bb0080]; [@bb0190]). Using the MMSE at baseline to align individuals according to their initial disease stage, [@bb0075] found increasing hippocampal atrophy with advancing disease progression within individuals. Additionally, [@bb0030] and [@bb0130] used self-modeling regression and Bayesian Gaussian process regression respectively to place individuals according to their disease stage and model declines in whole brain and hippocampal volume. Using the MMSE to align individuals according to their disease severity as a simple approach, our findings are in line with the results of those previous studies and we further show that other regions besides the hippocampus are associated with cognitive decline as a proxy for disease severity *within* individuals. Moreover, these associations were only observed in individuals with aggregated amyloid.

The most pronounced effect of modeling disease progression by decreasing MMSE compared to follow-up time or age was in the spatial pattern of associations observed in individuals with normal and with abnormal amyloid: Using time or age abnormal and normal amyloid participants showed, albeit with smaller atrophy rates, similar anatomical patterns; but when we used MMSE to model disease progression, we found widespread regional associations in individuals with abnormal amyloid across the clinical stages, whereas only few associations were found in amyloid normal individuals, most of which for cognitively normal individuals. In individuals with abnormal amyloid, associations with cognitive decline were strongest for regions including the hippocampus, superior and middle temporal pole and insula, which have been associated with cognitive dysfunction in AD ([@bb0025]; [@bb0035]). In individuals with normal amyloid, we observed most associations of regional atrophy rates and cognitive decline for cognitively normal individuals in frontal and temporal regions (although these effects did not survive correction for multiple testing). These regions have previously been associated with cognitive performance in 'normal' aging in the absence of amyloid pathology ([@bb0005]). However, when additionally correcting for age the results remained unchanged in regions that included the left superior temporal pole, olfactory gyrus and right Heschl\'s gyrus (see Inline Supplementary Fig. 3), areas that have been reported to be affected in frontotemporal dementia ([@bb0110]; [@bb0150]).This suggests that these alterations are not due to 'normal aging', but rather may reflect that some of these individuals have non-AD pathology.

By modeling atrophy as a function of MMSE, we observed a much less steep atrophy rate of 0.7% per 1 point decline on the MMSE compared to 2.1% with 1.29 point decline on the MMSE per year or 1.52% with 0.28 point decline on the MMSE per year of age when modeling atrophy as a function of time or aging, respectively. Possibly, when individuals are not aligned according to their initial disease severity, the steeper slopes may reflect differences between individuals who were in early and those who were in more advanced stages of the disease at their first visit. Our results suggest that modeling GM atrophy as a function of MMSE shows involvement of anatomical areas that seem to be specifically related to cognitive decline in AD. Still, the slopes for the MMSE model were less steep as compared to the other models, and so we cannot exclude the possibility that GM atrophy in other anatomical areas as observed in the time and age models may have yet to affect the MMSE, or that those areas may be related to decline in more specific neuropsychological domains. Future research should further investigate this question by studying how GM atrophy relates to decline on specific neuropsychological tests scores.

Compared to AD dementia, individuals with prodromal AD showed steeper atrophy slopes in age and MMSE models, but not in time models, suggesting that GM atrophy most closely relates with increasing age and decline on MMSE within prodromal AD individuals. Possibly, these findings can be explained due to increased variance in this group of individuals, while participants with dementia might start to show plateau or floor effects in either MMSE and/or atrophy rates. At a regional level, we found similar atrophy patterns between preclinical AD and prodromal AD for models based on time and age in individuals with abnormal amyloid. Compared to prodromal AD participants with AD dementia showed steeper atrophy slopes mostly in temporal regions for time and less steep atrophy slopes mostly in frontoparietal regions for age models. These results suggest that while GM volumes in the temporal lobes continue to decline over time in the dementia stage, atrophy is most associated with increasing age within individuals in the prodromal stage of the disease. Previous studies found higher atrophy rates for younger ages especially in dementia ([@bb0040]; [@bb0060]). However, these studies used baseline age to align individuals while we model the effect of aging within individuals. Regional atrophy as modeled over time and aging were also widespread in both samples with steeper slopes for individuals with abnormal amyloid and most pronounced in the medial temporal lobes, especially in the hippocampus. These results provide further support for the notion that amyloid aggregation is not part of normal aging and suggest that atrophy of the hippocampus is not specific for AD per se ([@bb0045]; [@bb0155]), but rather the rate of hippocampal atrophy.

Finally, model fit comparisons showed that the time model showed the best model fit. However, when additionally including time or age to the MMSE model (and similarly MMSE to the age and time model) effects remained comparable and these refitted models significantly improved model fit compared to the original models, suggesting that adding information on where individuals are in their disease trajectory explains additional variance GM atrophy. These findings further suggest that time, aging and decline on MMSE all explained part of the variance in GM atrophy within individuals. Future research should further investigate the possibility to develop composite measures that combine time or age with decline on MMSE, and should test whether this could improve estimates of GM atrophy over time.

Strengths of our study are the large number of individuals, which we were able to include from ADNI, and patients with different levels of cognitive impairment with and without biomarker evidence of AD over a long follow-up period of up to 10 years. A potential limitation of our approach is the use of MMSE as a measure for general cognitive functioning in this study. The MMSE is a cognitive screening tool that might not adequately capture subtle cognitive impairment and cognitive decline ([@bb0200]), and this may have contributed to the less steep atrophy slopes we observed. Although the MMSE is widely used and readily available for most studies, future research should further investigate how atrophy correlates with other measures that are more sensitive to subtle cognitive decline and to specific cognitive domains, which might relate to distinct, regional atrophy patterns. Furthermore, our sample of individuals with normal amyloid included only few dementia cases, which might have contributed to the weaker associations of MMSE and GM atrophy. Future research should further investigate the association of GM atrophy with time, age and cognitive decline in larger samples of individuals with non-AD dementia. Another possible limitation of our study might be in amyloid status classification. Here, we used PET when available, and otherwise CSF results were used to classify participants. Although these measures correlate ([@bb0225]), they may reflect different aspects of amyloid pathology ([@bb0105]; [@bb0135]; [@bb0165]), since PET tracers directly bind to amyloid fibrils, while in CSF amyloid accumulation is measured indirectly by decreasing levels of soluble Aβ1--42. By using PET as first criterion for amyloid abnormality we classified some participants as amyloid normal although they had abnormal levels of CSF Aβ1--42 (*n* = 76, 8.4%) and vice versa (*n* = 38, 4.2%). Given that this discordance occurred in \<10% of individuals, however, it is unlikely to have influenced the results. Finally, scans included in the present study were obtained with different field strengths. Although we ensured that, within subjects, the same field strength was used, and we adjusted for this variable in all the models, these field strengths may still have influenced our estimates on grey matter atrophy. Additional post-hoc analyses stratifying analyses for field strength showed that for abnormal amyloid individuals, estimates of grey matter and hippocampal volumes for 1.5 Tesla scans were slightly higher, those for 3 Tesla scans slightly lower as compared to the original estimates, which were based on all individuals with abnormal amyloid (see Inline Supplementary Table 11). Importantly, individuals with 1.5 Tesla scans (who were most often included at the start of the study) also showed steeper decline on the MMSE, while individuals with 3 Tesla scans showed less steep decline on the MMSE over time. For individuals with normal amyloid, stratifying by field strength resulted in similar estimates for all outcome measures in all models. These results suggest that differences in subsample characteristics might have driven these differences, but not necessarily field strength per se.

5. Conclusion {#s0070}
=============

One challenge in AD research is the estimation of where an individual is along their disease trajectory. Here, we modeled GM decline as a function of MMSE, in this way aligning individuals according to their disease severity and compared associations to those using follow-up time or aging. Our results suggest that modeling GM with MMSE decline within individuals, as a proxy for disease progression, provides smaller atrophy rates than those based on follow-up time or aging and are specific for cognitive decline in individuals with evidence of amyloid pathology.
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[^2]: Data are presented as *N* (%), mean (SD), or median (Q1-Q3), where appropriate. n.a., not applicable; n.s. not significant after adjustment for multiple comparisons.

[^3]: Available for *n* = 333.

[^4]: Available for *n* = 493.

[^5]: For ApoE ε4 carriers.

[^6]: Data are presented as β ± SE \[t ratio\] and in percentages (95% CI) for annual atrophy rates. Estimates are based on raw values/scores and were estimated with linear mixed models. The models included the terms age, sex, education, field strength, total intracranial volume (for grey matter volumes) and follow-up time in years for estimates of the total group. We additionally included baseline diagnosis and the interaction term follow-up time × diagnosis for effects per clinical stage. Annual atrophy rates are based on estimates of annual decline divided by mean volumes at baseline for the total group or respective diagnosis for results per clinical stage. GM, grey matter.

[^7]: *p* \< .01.

[^8]: *p* \< .001.

[^9]: Data are presented as β ± SE \[t ratio\] and in percentages (95% CI) for annual atrophy rates. Estimates are based on raw values/scores and were estimated with linear mixed models. The models included the terms sex, education, field strength, total intracranial volume (for grey matter volumes) and age in years for estimates of the total group. We additionally included baseline diagnosis and the interaction term age × diagnosis for effects per clinical stage. Annual atrophy rates are based on estimates of annual decline divided by mean volumes at baseline for the total group or respective diagnosis for results per clinical stage. GM, grey matter.

[^10]: *p* \< .05

[^11]: *p* \< .01

[^12]: *p* \< .001.

[^13]: Data are presented as β ± SE \[t ratio\] and in percentages (95% CI) for annual atrophy rates. Estimates are based on raw values/scores and were estimated with linear mixed models. The models included the terms age, sex, education, field strength, total intracranial volume and MMSE for estimates of the total group. We additionally included baseline diagnosis and the interaction term MMSE × diagnosis for effects per clinical stage. Atrophy rates per 1 score decline on the MMSE are based on longitudinal estimates divided by mean volumes at baseline for the total group or respective diagnosis for results per clinical stage. GM, grey matter.

[^14]: *p* \< .05.

[^15]: *p* \< .01.

[^16]: *p* \< .001.

[^17]: Data are presented as β ± SE \[t ratio\] and in percentages (95% CI) for annual atrophy rates. Estimates are based on raw values/scores and were estimated with linear mixed models. The models included the terms age, sex, education, field strength, total intracranial volume and MMSE for estimates of the total group. We additionally included baseline diagnosis and the interaction term MMSE × diagnosis for effects per clinical stage. Atrophy rates per 1 score decline on the MMSE are based on longitudinal estimates divided by mean volumes at baseline for the total group or respective diagnosis for results per clinical stage. GM, grey matter.

[^18]: *p* \< .05.

[^19]: *p* \< .01.

[^20]: *p* \< .001.
